pentobarbital will lower the level or result of saxagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.
pentobarbital will decrease the extent or effect of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Mysterious.
pentobarbital will decrease the extent or outcome of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will lessen the extent or effect of losartan by influencing hepatic enzyme CYP2C9/10 metabolism. Insignificant/Significance Mysterious.
pentobarbital will decrease the extent or outcome of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will minimize the level or effect of tipranavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
Stay clear of; coadministration with CYP3A inducers may lead to lessened plasma concentrations of elvitegravir and/or perhaps a concomitantly administered protease inhibitor and bring on lack of therapeutic outcome also to possible resistance
pentobarbital will reduce the level or impact of tolterodine by website influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will minimize the level or result of cyclosporine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital decreases effects of hemin by pharmacodynamic antagonism. Use Caution/Observe. Drugs that raise delta-aminolevulinic acid synthetase may possibly lessen hemin outcome.
pentobarbital will decrease the level or outcome of tamoxifen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will reduce the level or result of atorvastatin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
Barbiturates can induce hepatic microsomal enzymes resulting in greater metabolism and reduced anticoagulant reaction of oral anticoagulants (eg, warfarin, acenocoumarol, dicumarol, and phenprocoumon); patients stabilized on anticoagulant therapy may well need dosage changes if barbiturates are added to or withdrawn from their dosage routine
pentobarbital will lower the level or result of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.